{"title":"Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer via EGFR inhibition: molecular design, synthesis, analysis and screening","link":"http://pubs.rsc.org/en/Content/ArticleLanding/2024/RA/D4RA01424C","date":null,"content":"<div><p><img src=\"/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D4RA01424C\" /></p></div><div><i><b>RSC Adv.</b></i>, 2024, <b>14</b>,11368-11387<br /><b>DOI</b>: 10.1039/D4RA01424C, Paper</div><div><img alt=\"Open Access\" src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/open_access_blue.png\" /> Open Access</div><div><a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\"> <img src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/CCBY-NC.png\" alt=\"Creative Commons Licence\" /></a>Â  This article is licensed under a <a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\">Creative Commons Attribution-NonCommercial 3.0 Unported Licence.</a></div><div>Syed Faizan, Sirajunisa Talath, Adil Farooq Wali, Umme Hani, Nazima Haider, Subhankar P. Mandal, B. R. Prashantha Kumar<br />Our study introduces novel symmetrical and asymmetrical dihydropyridines as breast cancer inhibitors, showing cytotoxicity against MCF-7 cells and EGFR kinase inhibition. Molecular docking and dynamics validate superior binding to Lapatinib.<br />The content of this RSS Feed (c) The Royal Society of Chemistry</div>","author":"","siteTitle":"RSC - RSC Adv. latest articles","siteHash":"da3e282678330308414c63a405ade89dd3738fcce2936ca8a2fe3a6d7e967d99","entryHash":"54886a4da6b9c007cfc336e7a2e1da298d7efd76996e66422d3a81a2ae2561a7","category":"Environment"}